Mangalam Drugs And Organics Limited — Board Meeting, 07-08-2025: Outcome of Board Meeting

Mangalam Drugs has announced a board meeting where it approved the consolidated financial results for the quarter ended June 30, 2025. The company reported a total income from operations of ₹57.35 Cr, down from ₹76.54 Cr in the same quarter last year. It posted a net loss of ₹13.80 Cr, compared to a net profit of ₹2.68 Cr previously.

The Board also confirmed progress on the merger scheme with Mangalam Laboratories and Shri JB Pharma. This strategic move awaits final NCLT approval, with creditor and shareholder meetings set for August 12. This merger aims to streamline operations and enhance market presence for the bulk drug manufacturer.